Trials / Completed
CompletedNCT00189917
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMVAMUNE (MVA-BN) | 1x10E08 TCID50, subcutaneous vaccination |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-12-01
- First posted
- 2005-09-19
- Last updated
- 2019-01-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00189917. Inclusion in this directory is not an endorsement.